Market Overview

Jefferies Reiterates Underperform Rating, $4 PT on Halozyme Therapeutics


In a report published Wednesday, Jefferies reiterated its Underperform rating and $4.00 price target on Halozyme Therapeutics (NASDAQ: HALO).

Jefferies noted, “SC Herceptin EU approval is expected in 1H13; its commercial success will be key to ultimate validation of rHuPH20 technology & further valuation upside in HALO. We continue to view SC Herceptin commercial potential as low. Given delays in Herceptin biosimilar EU market entry & potentially expedited development of its T-DM1 in HER2+ BC adjuvant setting, Roche's focus on SC Herceptin seems to have diminished.”

Halozyme Therapeutics closed on Tuesday at $8.03.

Latest Ratings for HALO

Dec 2020BerenbergInitiates Coverage OnBuy
Nov 2020Wells FargoMaintainsOverweight
Jul 2020Piper SandlerMaintainsOverweight

View More Analyst Ratings for HALO
View the Latest Analyst Ratings


Related Articles (HALO)

View Comments and Join the Discussion!

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

Latest Ratings

CMARaymond JamesMaintains72.0
ACRSSVB LeerinkMaintains21.0
GHSVB LeerinkMaintains190.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at